Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Hematology›Condition·Updated Jun 27, 2026·v1

Polycythemia Vera

Polycythemia vera is a JAK2-driven MPN defined by erythrocytosis, thrombotic risk, and potential for transformation to myelofibrosis or AML. Diagnosis requires JAK2 mutation testing, low serum EPO, bone marrow panmyelosis, and exclusion of secondary causes. Management is risk-adapted: all patients receive phlebotomy to Hct <45% and low-dose aspirin; high-risk patients additionally require cytoreduction (hydroxyurea first-line, interferon for younger patients, ruxolitinib for resistance). With optimal care, median survival is ~17 years; thrombosis remains the leading cause of death.

High Evidence154 references·6,030 words·25 min read·v1
polycythemia veraJAK2 V617Fmyeloproliferative neoplasmerythrocytosishydroxyurearuxolitinibinterferonphlebotomythrombosishematology

Quick Reference

RxDrug of choiceFirst-line: [[hydroxyurea]] 500-1000 mg PO daily for high-risk patients. Alternative 1st-line: [[ropeginterferon alfa-2b]] 250-500 µg SC every 2 weeks. For HU-resistant/intolerant: [[ruxolitinib]] 10 mg PO BID.
AltAlternatives[[Peginterferon alfa-2a]] 90-180 µg SC weekly; [[rusfertide]] (hepcidin mimetic, investigational) 40-80 mg SC weekly; [[buserelin]] not used in PV.
⊘AvoidAvoid non-dihydropyridine CCBs (diltiazem, verapamil), no direct role in PV; avoid aspirin if platelet count >1000 × 10⁹/L; restrict hydroxyurea in pregnancy; avoid ruxolitinib in pregnancy (insufficient safety data).
DxTest of choiceJAK2 V617F mutation testing on peripheral blood (first-line molecular test); if negative, JAK2 exon 12 sequencing. Bone marrow biopsy with trephine core for histologic confirmation.
ScKey scoreIWG-MRT risk stratification: low-risk (age <60 + no prior thrombosis) vs high-risk (age ≥60 or prior thrombosis). Also QRISK3 score (>7.5% predicts 2.1x HR for thrombosis).
→When to referNew diagnosis for risk stratification and cytoreduction decision; suspected disease transformation (cytopenias, splenomegaly, blasts); pregnancy; intolerance/resistance to first-line therapy; consideration for clinical trial (rusfertide, novel JAK inhibitors).
All PV patients need phlebotomy to Hct <45% and low-dose aspirin. High-risk patients (age >60 or prior thrombosis) need cytoreduction, start hydroxyurea; use interferon in younger/pregnant patients; ruxolitinib for HU failures. Untreated thrombosis risk is 5%/year; with optimal management, median survival is 17 years.
Polycythemia vera (PV) is a chronic myeloproliferative neoplasm driven by a JAK2 V617F mutation in >95% of cases, leading to clonal erythroid expansion and markedly elevated thrombotic risk. Management centers on maintaining hematocrit <45% via phlebotomy, universal low-dose aspirin, and cytoreductive therapy for high-risk patients (age >60 or prior thrombosis). First-line cytoreduction is hydroxyurea; ropeginterferon alfa-2b and ruxolitinib are key alternatives. Untreated, 5-year mortality exceeds 50% from thrombosis; with modern therapy, median survival is ~17 years.

Overview and Recommendations

Background

  • •Polycythemia vera (PV) is a JAK2-driven myeloproliferative neoplasm defined by clonal expansion of hematopoietic stem cells, causing erythrocytosis, increased red cell mass, and a 5-fold elevated risk of arterial and venous thrombosis. The JAK2 V617F mutation, found in >95% of patients, constitutively activates JAK-STAT signaling, hypersensitizing progenitors to erythropoietin and driving trilineage hyperplasia.
  • •PV is the most common MPN, with an annual incidence of 0.5-4.0 per 100,000 and a prevalence of ~65,000 in the United States. Median age at diagnosis is 60-65 years; it is rare before age 40. A slight male predominance exists (M:F ~1.2:1). Survival has improved from 55% to 70% at 10 years over recent decades, but excess mortality persists (SMR ~1.6) driven by thrombosis (40-50% of deaths) and transformation to myelofibrosis or AML.
  • •The central molecular mechanism is constitutive JAK2 activation. In ~95% of cases, a valine-to-phenylalanine substitution at codon 617 (V617F) in the pseudokinase domain relieves autoinhibition. In the remaining 2-5%, JAK2 exon 12 mutations produce a similar phenotype, often with isolated erythrocytosis. Mutation order matters: when JAK2 V617F precedes TET2 mutation, the MPN phenotype is more aggressive with earlier diagnosis and higher hemoglobin levels.
  • •The natural history of PV progresses through three phases: (1) the polycythemic phase, erythrocytosis, often with leukocytosis and thrombocytosis; (2) post-PV myelofibrosis, bone marrow fibrosis, cytopenias, splenomegaly, and constitutional symptoms, occurring in 15-20% at 10 years; and (3) blast phase, transformation to AML or MDS, with a cumulative incidence of 5-10% at 20 years. The landmark CYTO-PV trial (2013) established that targeting hematocrit <45% halves the annual thrombosis rate (5.0% vs 1.1%) and is the foundation of modern management.

Evaluation

  • •Suspect PV in any patient with unexplained erythrocytosis (hemoglobin >16.5 g/dL in men, >16.0 g/dL in women; hematocrit >49% in men, >48% in women), especially when accompanied by splenomegaly, pruritus after warm baths, or a history of unprovoked thrombosis.
  • •Ask about headache, dizziness, fatigue, blurred vision, tinnitus, and paresthesias, all symptoms of hyperviscosity. Inquire specifically about aquagenic pruritus (intense itching after showering), a highly characteristic symptom reported in 30-50% of patients. Also ask about prior thrombotic events (stroke, MI, DVT, PE, splanchnic vein thrombosis) and bleeding (epistaxis, GI bleeding from platelet dysfunction).
  • •Examine for plethoric facies with ruddy cyanosis, conjunctival injection, retinal vein tortuosity, and splenomegaly (palpable in ~70%). Hepatomegaly is present in ~40%. Check for signs of hyperviscosity: neurologic deficits, papilledema, or focal findings from prior silent strokes. Measure blood pressure, hypertension is present in 30-50%.
  • •Order a complete blood count with differential. Classic PV shows erythrocytosis (Hb >16.5/16.0 g/dL), often with leukocytosis (WBC >11 × 10⁹/L in ~50%) and thrombocytosis (platelets >400 × 10⁹/L in ~40%). A normal WBC and platelet count does not exclude PV.
  • •Measure serum erythropoietin (EPO) level, a low EPO is a major WHO diagnostic criterion for PV. A normal or elevated EPO suggests secondary erythrocytosis (e.g., sleep apnea, COPD, high-altitude living, SGLT2 inhibitor use, or erythropoietin-secreting tumors).
  • •Perform JAK2 V617F mutation testing on peripheral blood or bone marrow as the initial molecular test. If negative, test for JAK2 exon 12 mutations. The variant allele frequency (VAF) of JAK2 V617F correlates with disease burden; a VAF >50% is associated with higher thrombotic risk and more pronounced erythrocytosis.
  • •Bone marrow biopsy with trephine core is mandatory for definitive diagnosis per WHO criteria. Key histologic findings: panmyelosis (hypercellular marrow with trilineage hyperplasia), pleomorphic megakaryocytes with hyperlobated nuclei ("staghorn" forms), and absent or minimal reticulin fibrosis (grade 0-1). Grade 2-3 fibrosis suggests primary myelofibrosis or masked PV.
  • •Apply the WHO diagnostic criteria: major criteria include hemoglobin >16.5/16.0 g/dL (or hematocrit >49%/48%), bone marrow panmyelosis, JAK2 mutation, and low serum EPO. Minor criteria: subnormal serum EPO level. Diagnosis requires all three major criteria or first two major plus the minor criterion.
  • •Exclude secondary causes of erythrocytosis: sleep apnea (polysomnography if suggested by snoring, daytime somnolence), chronic hypoxemia (pulse oximetry, arterial blood gas), high-affinity hemoglobin (Hb-oxygen dissociation curve), and erythropoietin-secreting tumors (renal cell carcinoma, cerebellar hemangioblastoma, hepatocellular carcinoma). Consider SGLT2 inhibitor use as a reversible cause.
  • •Assess thrombotic risk at diagnosis using the IWG-MRT risk stratification: low risk (age <60 and no prior thrombosis), high risk (age ≥60 or prior thrombosis). No formal intermediate-risk category exists in the classic two-tier system, though some guidelines recognize an intermediate group. Also calculate the QRISK3 score if age-appropriate, as a score >7.5% identifies additional high-risk patients.
  • •Also consider imaging for suspected thrombosis: CT/MR venography for abdominal or cerebral venous thrombosis; ultrasound for splenomegaly quantitation. Imaging is driven by clinical suspicion, not routine surveillance.

Management

  • •Initiate phlebotomy for all patients with hematocrit >45% regardless of risk status. Target hematocrit <45% (both sexes per CYTO-PV). Remove 300-500 mL of blood once or twice weekly until target is reached, then as needed to maintain target. Typical maintenance frequency is every 1-3 months.
  • •Start low-dose aspirin (81-100 mg PO daily) for all patients without contraindications (history of major bleeding, platelet count >1000 × 10⁹/L due to risk of acquired von Willebrand syndrome). The ECLAP trial demonstrated a 60% reduction in thrombotic events with aspirin.
  • •For high-risk patients (age ≥60 years or prior thrombosis), add cytoreductive therapy to phlebotomy and aspirin. First-line: 500 mg PO daily, titrated by 500 mg increments every 1-2 weeks to maintain hematocrit <45% and platelet count <400 × 10⁹/L. Typical maintenance dose: 500-2000 mg daily. Monitor CBC every 2-4 weeks during titration, then every 3 months.
  • •Alternative first-line for younger patients (age <50), those desiring pregnancy, or those with intolerance to hydroxyurea: 250 µg SC every 2 weeks, titrated to 500 µg SC every 2 weeks. Provides 70-80% complete hematologic response and reduces JAK2 VAF by 30-50% over 36 months (PROUD-CONTI study). 90 µg SC weekly, titrated to 180 µg weekly, is an alternative.
  • •For hydroxyurea-resistant or intolerant patients, switch to 10 mg PO twice daily. The RESPONSE trial showed 21% achieving hematocrit control with ≥35% spleen reduction at 32 weeks vs 1% with best available therapy (NNT = 5). The MAJIC-PV trial confirmed superior complete response (43% vs 26%). Monitor CBC, spleen size, and symptoms monthly initially.
  • •For phlebotomy-dependent patients who cannot tolerate or decline cytoreduction, consider (hepcidin mimetic) 40 mg SC weekly, titrated to 80 mg SC weekly. The REVIVE trial showed 60% achieved hematocrit control without phlebotomy vs 17% with placebo. This agent is investigational in the US; check local availability.
  • •Monitor for iron deficiency (ferritin <30 ng/mL) during chronic phlebotomy. Do not routinely replete iron, mild iron deficiency limits erythropoiesis and reduces phlebotomy frequency. Supplement iron only for symptomatic iron deficiency (fatigue, pica, restless legs) while monitoring hematocrit closely.
  • •Avoid combining aspirin with antiplatelet agents (clopidogrel, prasugrel) or anticoagulants (warfarin, DOACs) unless a separate thrombotic indication exists (e.g., atrial fibrillation, mechanical heart valve). The bleeding risk is high in PV due to platelet dysfunction.
  • •Do not administer cytoreductive therapy to low-risk patients unless they have severe symptoms (refractory pruritus, symptomatic splenomegaly) or require >6-8 phlebotomies per year. The NNT for cytoreduction to prevent one thrombosis in low-risk patients is ~50 over 5 years, making the risk-benefit unfavorable.
  • •Refer to a hematologist with expertise in MPNs at diagnosis for confirmation of risk stratification and initiation of cytoreductive therapy. Refer urgently for suspected disease transformation (worsening splenomegaly, cytopenias, ≥5% blasts on peripheral smear).
  • •Criteria to consider transition to post-PV myelofibrosis management (refer to MF protocols): new-onset splenomegaly, unexplained cytopenias (anemia, thrombocytopenia), constitutional symptoms (fevers, night sweats, weight loss), or rising reticulin fibrosis on repeat bone marrow biopsy.
  • •Discharge criteria for hospitalized patients with acute thrombosis: therapeutic anticoagulation established, hematocrit <45% (phlebotomy as needed), cytoreduction initiated if indicated, and follow-up with hematology within 2 weeks.

Board Review — High Yield

  • •JAK2 V617F mutation, present in >95% of PV; constitutive JAK-STAT activation; VAF correlates with disease burden and thrombotic risk.
  • •CYTO-PV trial, targeting hematocrit <45% reduces major thrombosis from 5.0% to 1.1% per year (NNT=6 over 3 years).
  • •ECLAP trial, low-dose aspirin (81-100 mg/day) reduces thrombotic events by 60% in PV.
  • •Aquagenic pruritus, pathognomonic symptom (30-50%); worse after warm bath; driven by histamine release from basophils.
  • •IWG-MRT risk stratification, two variables only: age ≥60 years and prior thrombosis; defines high-risk vs low-risk.
  • •Hydroxyurea, first-line cytoreduction for high-risk PV; reduces thrombosis but does not lower JAK2 VAF; risk of leg ulcers and potential leukemogenesis with >5 years use (NNH=22).
  • •Ropeginterferon alfa-2b, first-line for younger patients; achieves molecular response (30-50% JAK2 VAF reduction); preferred in pregnancy.
  • •Ruxolitinib, second-line for HU-resistant/intolerant; RESPONSE trial (N=222) showed 21% hematocrit control + spleen reduction; monitor for herpes zoster reactivation.
  • •Post-PV myelofibrosis, 15-20% at 10 years; diagnosed by bone marrow fibrosis, cytopenias, splenomegaly; use DIPSS/DIPSS-plus for prognosis.
  • •Serum erythropoietin, low in PV (major diagnostic criterion); normal or high suggests secondary erythrocytosis.

Deep Dive — Evidence Details

References

  1. [1]

    Kiladjian JJ, Chevret S, Dosquet C et al.. “Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21911721 ↗

    L1RCTCited in: Definition and Epidemiology, Management Overview, Special Populations
  2. [2]

    Marchioli R, Finazzi G, Specchia G et al.. “Cardiovascular events and intensity of treatment in polycythemia vera.” The New England journal of medicine (2012). PMID: 23216616 ↗

    L1RCTCited in: Definition and Epidemiology, Management Overview, Special Populations
  3. [3]

    Pardanani A, Gotlib JR, Jamieson C et al.. “Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21220608 ↗

    L4TRIAL_NONRANDOMCited in: Definition and Epidemiology, Management Overview, Prognosis and Prognostic Factors, Special Populations
  4. [4]

    Lee J, Axilbund J, Dalton WB et al.. “A Polycythemia Vera JAK2 Mutation Masquerading as a Duodenal Cancer Mutation.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 27956534 ↗

    L4CASE_REPORTCited in: Definition and Epidemiology, Clinical Presentation, Imaging, Management Overview, Special Populations
  5. [5]

    Teofili L, Giona F, Martini M et al.. “Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17369568 ↗

    L3OTHERCited in: Definition and Epidemiology, Clinical Presentation, Special Populations
  6. [6]

    Hultcrantz M, Kristinsson SY, Andersson TM et al.. “Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 22802311 ↗

    L2OTHERCited in: Definition and Epidemiology, Special Populations
  7. [7]

    Modi NB, Dinh P, Ajari I. “Multiple-Dose Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Subcutaneous Rusfertide, a Hepcidin Mimetic, in Healthy Subjects.” Clinical pharmacology in drug development (2025). PMID: 39888264 ↗

    L1RCTCited in: Definition and Epidemiology
  8. [8]

    Batyrbekova N, Landtblom AR, Hultcrantz M et al.. “Risk of Transformation to Acute Myeloid Leukaemia and Myelodysplastic Syndromes in Patients With Myeloproliferative Neoplasms Over Attained Age and Time Since Diagnosis: A Nationwide Cohort Study.” European journal of haematology (2026). PMID: 41717866 ↗

    L2COHORTCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation, Special Populations
  9. [9]

    Bove FJ, Greek A, Gatiba R et al.. “Cancer Incidence among Marines and Navy Personnel and Civilian Workers Exposed to Industrial Solvents in Drinking Water at US Marine Corps Base Camp Lejeune: A Cohort Study.” Environmental health perspectives (2024). PMID: 39446420 ↗

    L2COHORTCited in: Definition and Epidemiology
  10. [10]

    Barbui T, Scandura JM. “Toward new therapy end points in polycythemia vera: targeting clonal and inflammatory pathways.” Blood advances (2026). PMID: 41370203 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  11. [11]

    Szuber N, Tefferi A, Gangat N. “JAK2 wild-type erythrocytosis: concept, differential diagnosis, diagnostic steps, and treatment approaches.” Hematology. American Society of Hematology. Education Program (2025). PMID: 41347984 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation
  12. [12]

    Szuber N, Guglielmelli P, Gangat N. “Topics of Interest in Women With Myeloproliferative Neoplasms.” American journal of hematology (2025). PMID: 40084464 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  13. [13]

    Barbui T, Stefano V, Rossi E et al.. “Thrombosis-Driven Disease Progression in JAK2-Mutant Polycythemia Vera and Essential Thrombocythemia: Reassessing Risk-Based Management.” American journal of hematology (2025). PMID: 40062566 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  14. [14]

    Tefferi A, Gangat N, Loscocco GG et al.. “Essential Thrombocythemia: A Review.” JAMA (2025). PMID: 39869325 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  15. [15]

    Spivak JL. “Myeloproliferative Neoplasms: Challenging Dogma.” Journal of clinical medicine (2024). PMID: 39598101 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  16. [16]

    Tremblay D, Kremyanskaya M, Mascarenhas J et al.. “Diagnosis and Treatment of Polycythemia Vera: A Review.” JAMA (2025). PMID: 39556352 ↗

    L5REVIEW_NARRATIVECited in: Definition and Epidemiology
  17. [17]

    Sankar K, Stein BL. “Do All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction?” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 30545998 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Management Overview
  18. [18]

    Khan MA, Naqvi SAA, Camoriano JK et al.. “Predictors of Symptom Scores in Myeloproliferative Neoplasms: A Real-World Retrospective Cohort Study.” Cancer medicine (2025). PMID: 41317085 ↗

    L2COHORTCited in: Risk Factors and Prevention, Clinical Presentation, Special Populations
  19. [19]

    Björkholm M, Derolf AR, Hultcrantz M et al.. “Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21537037 ↗

    L3OTHERCited in: Risk Factors and Prevention, Clinical Presentation, Management Overview, Special Populations
  20. [20]

    Barbui T, Carobbio A, De Stefano V et al.. “Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.” Annals of hematology (2023). PMID: 38060001 ↗

    L1RCTCited in: Risk Factors and Prevention
  21. [21]

    Ngoc NT, Hau BB, Vuong NB et al.. “JAK2 rs10974944 is associated with both V617F-positive and negative myeloproliferative neoplasms in a Vietnamese population: A potential genetic marker.” Molecular genetics & genomic medicine (2022). PMID: 35996819 ↗

    L3SR_OBSCited in: Risk Factors and Prevention
  22. [22]

    Cohen I, Rozental A, Raanani P et al.. “Thrombosis in Low-Risk Polycythemia Vera: Insights From a Large Real-World Cohort.” Hematological oncology (2026). PMID: 42176275 ↗

    L2OTHERCited in: Risk Factors and Prevention, Management Overview
  23. [23]

    Larsson AE, Renlund H, Andréasson B et al.. “Polycythemia Vera and Essential Thrombocythemia: A Nationwide Population-Based Study on Treatment Patterns, Vascular Complications and Survival.” European journal of haematology (2026). PMID: 41531010 ↗

    L2OTHERCited in: Risk Factors and Prevention
  24. [24]

    Guy A, Mansier O, Decilap M et al.. “Thromboinflammation is associated with high thrombotic risk in patients with newly diagnosed myeloproliferative neoplasms.” Leukemia (2025). PMID: 41436639 ↗

    L2OTHERCited in: Risk Factors and Prevention
  25. [25]

    Mishra R, Bagga A, Sharafeldin N et al.. “Risk and Outcomes of Second Malignancies in Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasm: A SEER Database Analysis.” JCO oncology practice (2025). PMID: 41397215 ↗

    L2OTHERCited in: Risk Factors and Prevention
  26. [26]

    Gangat N, Szuber N, Tefferi A. “JAK2 Unmutated Erythrocytosis: 2026 Update on Diagnosis and Management.” American journal of hematology (2025). PMID: 41123216 ↗

    L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Clinical Presentation
  27. [27]

    Rivière E, Mansier O, Guy A et al.. “TRAKJAK: a complete blood count-based prediction of polycythemia vera at initial erythrocytosis workup to reduce financial and ecological costs.” The American journal of medicine (2025). PMID: 41109612 ↗

    L3OTHERCited in: Risk Factors and Prevention
  28. [28]

    Duminuco A, Vaghela R, Virdee S et al.. “QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasms.” Leukemia (2025). PMID: 40707675 ↗

    L3OTHERCited in: Risk Factors and Prevention
  29. [29]

    Ianotto JC, Curto-Garcia N, Lauermanova M et al.. “Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review.” Haematologica (2019). PMID: 30679326 ↗

    L5SR_OBSCited in: Histopathology and Molecular Biology
  30. [30]

    Spivak JL, Considine M, Williams DM et al.. “Two clinical phenotypes in polycythemia vera.” The New England journal of medicine (2014). PMID: 25162887 ↗

    L4OTHERCited in: Histopathology and Molecular Biology, Special Populations
  31. [31]

    Ortmann CA, Kent DG, Nangalia J et al.. “Effect of mutation order on myeloproliferative neoplasms.” The New England journal of medicine (2015). PMID: 25671252 ↗

    L4OTHERCited in: Histopathology and Molecular Biology
  32. [32]

    Kirschner M, Bornemann A, Schubert C et al.. “Transcriptional alteration of DNA repair genes in Philadelphia chromosome negative myeloproliferative neoplasms.” Annals of hematology (2019). PMID: 31748924 ↗

    L4TRIAL_NONRANDOMCited in: Histopathology and Molecular Biology
  33. [33]

    Mullally A, Lane SW, Ball B et al.. “Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.” Cancer cell (2010). PMID: 20541703 ↗

    L5OTHERCited in: Histopathology and Molecular Biology, Management Overview
  34. [34]

    Radich J. “The molecular biology of myeloproliferative disorders.” Cancer cell (2010). PMID: 20609348 ↗

    L5OTHERCited in: Histopathology and Molecular Biology
  35. [35]

    Kiem D, Wagner S, Magnes T et al.. “The Role of Neutrophilic Granulocytes in Philadelphia Chromosome Negative Myeloproliferative Neoplasms.” International journal of molecular sciences (2021). PMID: 34502471 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  36. [36]

    Kjær L. “Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms.” Cancers (2020). PMID: 32731609 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  37. [37]

    Bose P, Verstovsek S. “JAK2 inhibitors for myeloproliferative neoplasms: what is next?” Blood (2017). PMID: 28500170 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  38. [38]

    Saeidi K. “Myeloproliferative neoplasms: Current molecular biology and genetics.” Critical reviews in oncology/hematology (2015). PMID: 26697989 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  39. [39]

    Harrison CN, Garcia NC. “Management of MPN beyond JAK2.” Hematology. American Society of Hematology. Education Program (2014). PMID: 25696878 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  40. [40]

    Beer PA. “The pathogenesis of essential thrombocythemia.” Current opinion in hematology (2011). PMID: 21825979 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  41. [41]

    Scherber R, Mesa RA. “Future therapies for the myeloproliferative neoplasms.” Current hematologic malignancy reports (2011). PMID: 21080242 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  42. [42]

    Kvasnicka HM, Thiele J. “Prodromal myeloproliferative neoplasms: the 2008 WHO classification.” American journal of hematology (2010). PMID: 19844986 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  43. [43]

    Tefferi A, Skoda R, Vardiman JW. “Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.” Nature reviews. Clinical oncology (2009). PMID: 19806146 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  44. [44]

    Kandarpa M, Robinson D, Wu YM et al.. “Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38386293 ↗

    L3OTHERCited in: Histopathology and Molecular Biology, Special Populations
  45. [45]

    Roug AS, Nyvold CG, Juhl-Christensen C et al.. “A patient with a 20-year lag phase between JAK2-V617F+ myeloproliferation and NPM1-mutated AML arguing against a common origin of disease.” European journal of haematology (2011). PMID: 21689158 ↗

    L4CASE_REPORTCited in: Histopathology and Molecular Biology
  46. [46]

    Pescia C, Lopez G, Cattaneo D et al.. “The molecular landscape of myeloproliferative neoplasms associated with splanchnic vein thrombosis: Current perspective.” Leukemia research (2023). PMID: 38016412 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  47. [47]

    Putter JS, Seghatchian J. “Polycythaemia vera: molecular genetics, diagnostics and therapeutics.” Vox sanguinis (2021). PMID: 33634867 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  48. [48]

    Pavithran K, Pande SB. “Janus kinase inhibitors: jackpot or potluck?” Oncology reviews (2012). PMID: 25992203 ↗

    L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
  49. [49]

    Gerds AT, Gotlib J, Ali H et al.. “Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 36075392 ↗

    L1GUIDELINECited in: Clinical Presentation, Management Overview
  50. [50]

    Mesa RA, Jamieson C, Bhatia R et al.. “NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 28982745 ↗

    L1GUIDELINECited in: Clinical Presentation, Management Overview, Prognosis and Prognostic Factors
  51. [51]

    Mesa R, Jamieson C, Bhatia R et al.. “Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 27956542 ↗

    L1GUIDELINECited in: Clinical Presentation, Management Overview
  52. [52]

    Stein BL, Gotlib J, Arcasoy M et al.. “Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 25870379 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Management Overview
  53. [53]

    Quintás-Cardama A, Kantarjian H, Manshouri T et al.. “Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19826111 ↗

    L4TRIAL_NONRANDOMCited in: Clinical Presentation, Management Overview, Prognosis and Prognostic Factors, Special Populations
  54. [54]

    Pardanani A, Harrison C, Cortes JE et al.. “Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.” JAMA oncology (2015). PMID: 26181658 ↗

    L1RCTCited in: Clinical Presentation, Imaging, Management Overview, Prognosis and Prognostic Factors
  55. [55]

    Gangaraju R, Kim SJ, Dong JF et al.. “Thrombotic Thrombocytopenic Purpura Associated With Pegylated Interferon Alfa-2a Use in a Patient With Polycythemia Vera.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 28596255 ↗

    L4CASE_REPORTCited in: Clinical Presentation, Management Overview, Prognosis and Prognostic Factors
  56. [56]

    Tefferi A, Vainchenker W. “Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21220604 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Management Overview
  57. [57]

    Kander EM, Moliterno AR, Rademaker A et al.. “Practice Patterns in the Diagnosis and Treatment of Polycythemia Vera in the Post-JAK2 V617F Discovery Era.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 27697978 ↗

    L4OTHERCited in: Clinical Presentation, Management Overview, Special Populations
  58. [58]

    McFarland DC, Shaffer KM, Polizzi H et al.. “Prevalence of Physical Problems Detected by the Distress Thermometer and Problem List in Patients With Myeloproliferative Disorders.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 29223988 ↗

    L4OTHERCited in: Clinical Presentation
  59. [59]

    Tefferi A, Pardanani A. “Myeloproliferative Neoplasms: A Contemporary Review.” JAMA oncology (2015). PMID: 26182311 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors
  60. [60]

    Geyer H, Scherber R, Kosiorek H et al.. “Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 26598745 ↗

    L2OTHERCited in: Clinical Presentation, Management Overview, Prognosis and Prognostic Factors, Special Populations
  61. [61]

    Tam CS, Kantarjian H, Cortes J et al.. “Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19786661 ↗

    L3OTHERCited in: Clinical Presentation, Management Overview, Special Populations
  62. [62]

    Neumark N, Jalowiec KA, Tichelli A et al.. “Long-term real-world thrombotic and clinical outcomes in polycythemia vera - a hospital-based i2b2 cohort study.” Annals of hematology (2026). PMID: 41661348 ↗

    L3COHORTCited in: Clinical Presentation
  63. [63]

    Cai Y, Wang Y, Zhang P et al.. “Gender influences prognosis of classical BCR::ABL1 negative myeloproliferative neoplasms: a retrospective cohort study.” Discover oncology (2025). PMID: 41413374 ↗

    L3COHORTCited in: Clinical Presentation
  64. [64]

    Grinfeld J, Nangalia J, Baxter EJ et al.. “Classification and Personalized Prognosis in Myeloproliferative Neoplasms.” The New England journal of medicine (2018). PMID: 30304655 ↗

    L3OTHERCited in: Clinical Presentation, Prognosis and Prognostic Factors
  65. [65]

    Scott LM, Tong W, Levine RL et al.. “JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.” The New England journal of medicine (2007). PMID: 17267906 ↗

    L3OTHERCited in: Clinical Presentation
  66. [66]

    Nangalia J, Massie CE, Baxter EJ et al.. “Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.” The New England journal of medicine (2013). PMID: 24325359 ↗

    L3OTHERCited in: Clinical Presentation
  67. [67]

    Ellis MH, Barbui T, Tefferi A. “Polycythemia vera.” Mayo Clinic proceedings (2026). PMID: 41902804 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Management Overview
  68. [68]

    Ma X, Zhou Z, Gu S et al.. “Advances in the Diagnosis and Treatment of Myeloproliferative Neoplasms (MPNs).” Cancers (2025). PMID: 41097669 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  69. [69]

    Loscocco GG, Gangat N, Guglielmelli P et al.. “Mutation profiling of chronic myeloproliferative neoplasms: improving clinical-molecular prognostic models.” Expert review of molecular diagnostics (2025). PMID: 41074259 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Molecular Diagnostics and Biomarkers
  70. [70]

    Bruno R, Bolletta E, Gozzi F et al.. “Anterior Segment Involvement in Polycythemia Vera: A Case Report and Review of Literature.” Ocular immunology and inflammation (2025). PMID: 41114646 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  71. [71]

    Sharda AV, Bogue T, Barr A et al.. “Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in JAK2-Mutated Myeloproliferative Neoplasms.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 34400417 ↗

    L2OTHERCited in: Clinical Presentation, Special Populations
  72. [72]

    Wilkins BS, Erber WN, Bareford D et al.. “Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes.” Blood (2007). PMID: 17885079 ↗

    L4RCTCited in: Biopsy and Histologic Diagnosis
  73. [73]

    Bousquet M, Le Guellec S, Quelen C et al.. “Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations.” Human pathology (2006). PMID: 16949922 ↗

    L4COHORTCited in: Biopsy and Histologic Diagnosis
  74. [74]

    Thiele J, Kvasnicka HM. “Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading.” Pathobiology : journal of immunopathology, molecular and cellular biology (2007). PMID: 17587880 ↗

    L1REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  75. [75]

    Kvasnicka HM, Thiele J. “Classification of Ph-negative chronic myeloproliferative disorders--morphology as the yardstick of classification.” Pathobiology : journal of immunopathology, molecular and cellular biology (2007). PMID: 17587877 ↗

    L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
  76. [76]

    Hägglund H, Yavuz AS, Dreimane A et al.. “Graft-versus-mastocytosis effect after donor lymphocyte infusion: Proof of principle.” European journal of haematology (2020). PMID: 33010068 ↗

    L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis, Imaging
  77. [77]

    Chen L, Xiao H, Hu Z. “Cerebral Hemorrhage of a 50-Year-Old Female Patient with Polycythemia Vera.” Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (2019). PMID: 31126786 ↗

    L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis, Imaging
  78. [78]

    Putra J, Toor A, Noce TA et al.. “Multiple liver lesions in a patient with Budd-Chiari syndrome secondary to polycythemia vera.” Annals of hepatology (2015). PMID: 26019042 ↗

    L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis, Imaging
  79. [79]

    Vytrva N, Stacher E, Regitnig P et al.. “Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.” Archives of pathology & laboratory medicine (2014). PMID: 25171702 ↗

    L3CASE_REPORTCited in: Biopsy and Histologic Diagnosis
  80. [80]

    Mattei TA, Higgins M, Joseph F et al.. “Ectopic extramedullary hematopoiesis: evaluation and treatment of a rare and benign paraspinal/epidural tumor.” Journal of neurosurgery. Spine (2013). PMID: 23330877 ↗

    L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis
  81. [81]

    Mirza I, Frantz C, Clarke G et al.. “Transformation of polycythemia vera to chronic myelogenous leukemia.” Archives of pathology & laboratory medicine (2007). PMID: 17979493 ↗

    L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis
  82. [82]

    Slot S, van de Donk NWCJ, Otten RHJ et al.. “The value of bone marrow, liver, and spleen imaging in diagnosis, prognostication, and follow-up monitoring of myeloproliferative neoplasms: a systematic review.” Cancer imaging : the official publication of the International Cancer Imaging Society (2021). PMID: 33879266 ↗

    L1SR_OBSCited in: Imaging
  83. [83]

    Chiu YC, Chang WC, Chiu YC. “Early catheter-directed portal vein thrombolysis in myeloproliferative disorder-related diffuse mesenteric venous ischemia: A case report.” World journal of gastroenterology (2026). PMID: 41640868 ↗

    L4CASE_REPORTCited in: Imaging, Management Overview, Special Populations
  84. [84]

    Trifan G, Shafi N, Testai FD. “Implications of Janus Kinase 2 Mutation in Embolic Stroke of Unknown Source.” Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (2018). PMID: 30056970 ↗

    L5CASE_REPORTCited in: Imaging
  85. [85]

    Crespo AM, Abraira L, Guanyabens N et al.. “Recurrent Stroke with Rapid Development of Intracranial Stenoses in Polycythemia Vera.” Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (2016). PMID: 26825349 ↗

    L4CASE_REPORTCited in: Imaging
  86. [86]

    Lee J, Lim YM, Kim KK. “A case of spinal cord infarction caused by polycythemia vera.” Spinal cord (2015). PMID: 25900285 ↗

    L4CASE_REPORTCited in: Imaging
  87. [87]

    Huang HC, Wu YC, Shih LY et al.. “Reversible abnormal functional neuroimaging presentations in polycythemia vera with chorea.” Journal of neurology (2011). PMID: 21559940 ↗

    L4CASE_REPORTCited in: Imaging
  88. [88]

    Stanzani Maserati M. “Migraine attacks, aura, and polycythemia: a vasculoneural pathogenesis?” Journal of neural transmission (Vienna, Austria : 1996) (2010). PMID: 21161709 ↗

    L4CASE_REPORTCited in: Imaging
  89. [89]

    Sørensen AL, Bjørn ME, Riley CH et al.. “B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon-α2, or combination treatment.” European journal of haematology (2019). PMID: 31297883 ↗

    L1TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers
  90. [90]

    Taniguchi Y, Tanaka H, Luis EJ et al.. “Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms.” International journal of hematology (2017). PMID: 28780601 ↗

    L2TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers
  91. [91]

    Mejía-Ochoa M, Acevedo Toro PA, Cardona-Arias JA. “Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.” BMC cancer (2019). PMID: 31208359 ↗

    L1SR_OBSCited in: Molecular Diagnostics and Biomarkers
  92. [92]

    Marin Oyarzún CP, Carestia A, Lev PR et al.. “Neutrophil extracellular trap formation and circulating nucleosomes in patients with chronic myeloproliferative neoplasms.” Scientific reports (2016). PMID: 27958278 ↗

    L2TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers
  93. [93]

    Schmidt AE, Oh ST. “Pathology consultation on myeloproliferative neoplasms.” American journal of clinical pathology (2012). PMID: 22706852 ↗

    L5CASE_REPORTCited in: Molecular Diagnostics and Biomarkers
  94. [94]

    Mansier O, Lippert E, Benajiba L et al.. “A molecular signature predicts hematologic evolution in polycythemia vera patients.” Leukemia (2025). PMID: 40533498 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers
  95. [95]

    Handa S, Schaniel C, Tripodi J et al.. “HMGA2 overexpression with specific chromosomal abnormalities predominate in CALR and ASXL1 mutated myelofibrosis.” Leukemia (2024). PMID: 39715853 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers
  96. [96]

    Walter W, Nadarajah N, Hutter S et al.. “Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase.” Leukemia (2024). PMID: 39341969 ↗

    L2OTHERCited in: Molecular Diagnostics and Biomarkers
  97. [97]

    Tripodi J, Hoffman R, Tremblay D et al.. “Conventional Cytogenetic Analysis and Array CGH + SNP Identify Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis Patients Who Are at Risk for Disease Progression.” International journal of molecular sciences (2024). PMID: 38612873 ↗

    L3OTHERCited in: Molecular Diagnostics and Biomarkers
  98. [98]

    Chin-Yee B, Matyashin M, Cheong I et al.. “Secondary causes of elevated hemoglobin in patients undergoing molecular testing for suspected polycythemia vera in southwestern Ontario: a chart review.” CMAJ open (2022). PMID: 36347562 ↗

    L2REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
  99. [99]

    Yung Y, Lee E, Chu HT et al.. “Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.” International journal of molecular sciences (2021). PMID: 33440869 ↗

    L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
  100. [100]

    Leal AD, Thompson CA, Wang AH et al.. “Hormonal and Reproductive Factors and Risk of Myeloproliferative Neoplasms in Postmenopausal Women.” Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2015). PMID: 26564251 ↗

    L2RCTCited in: Staging
  101. [101]

    Santos FP, Kantarjian HM, Jain N et al.. “Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.” Blood (2009). PMID: 20008298 ↗

    L4TRIAL_NONRANDOMCited in: Staging
  102. [102]

    Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V et al.. “Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.” Blood (2015). PMID: 26261238 ↗

    L4TRIAL_NONRANDOMCited in: Staging
  103. [103]

    Rampal R, Mascarenhas J. “Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm.” Current opinion in hematology (2014). PMID: 24366192 ↗

    L5REVIEW_NARRATIVECited in: Staging
  104. [104]

    Tallarico M, Odenike O. “Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.” Current hematologic malignancy reports (2015). PMID: 25893311 ↗

    L5REVIEW_NARRATIVECited in: Staging
  105. [105]

    Tibes R, Mesa RA. “Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?” Leukemia & lymphoma (2011). PMID: 21599574 ↗

    L5REVIEW_NARRATIVECited in: Staging
  106. [106]

    Deadmond MA, Smith-Gagen JA. “Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.” Journal of cancer research and clinical oncology (2015). PMID: 25968903 ↗

    L2OTHERCited in: Staging
  107. [107]

    Prakash S, Hoffman R, Barouk S et al.. “Splenic extramedullary hematopoietic proliferation in Philadelphia chromosome-negative myeloproliferative neoplasms: heterogeneous morphology and cytological composition.” Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc (2012). PMID: 22388763 ↗

    L4OTHERCited in: Staging
  108. [108]

    Ruan GR, Jiang B, Li LD et al.. “MPL W515L/K mutations in 343 Chinese adults with JAK2V617F mutation-negative chronic myeloproliferative disorders detected by a newly developed RQ-PCR based on TaqMan MGB probes.” Hematological oncology (2010). PMID: 19274616 ↗

    L4OTHERCited in: Staging
  109. [109]

    Krahling T, Balassa K, Kiss KP et al.. “Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common TERT Polymorphism rs2736100.” Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2015). PMID: 26487696 ↗

    L3OTHERCited in: Staging
  110. [110]

    Gowin K, Thapaliya P, Samuelson J et al.. “Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients.” Haematologica (2012). PMID: 22419578 ↗

    L4OTHERCited in: Staging
  111. [111]

    Barbui T, Barosi G, Birgegard G et al.. “Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21205761 ↗

    L1GUIDELINECited in: Management Overview
  112. [112]

    Harrison CN, Nangalia J, Boucher R et al.. “Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37126762 ↗

    L1RCTCited in: Management Overview, Prognosis and Prognostic Factors
  113. [113]

    Vannucchi AM, Kiladjian JJ, Griesshammer M et al.. “Ruxolitinib versus standard therapy for the treatment of polycythemia vera.” The New England journal of medicine (2015). PMID: 25629741 ↗

    L1RCTCited in: Management Overview, Special Populations
  114. [114]

    Harrison C, Kiladjian JJ, Al-Ali HK et al.. “JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.” The New England journal of medicine (2012). PMID: 22375970 ↗

    L1RCTCited in: Management Overview, Special Populations
  115. [115]

    Kremyanskaya M, Kuykendall AT, Pemmaraju N et al.. “Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera.” The New England journal of medicine (2024). PMID: 38381675 ↗

    L1RCTCited in: Management Overview
  116. [116]

    Verstovsek S, Kantarjian H, Mesa RA et al.. “Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.” The New England journal of medicine (2010). PMID: 20843246 ↗

    L4TRIAL_NONRANDOMCited in: Management Overview, Special Populations
  117. [117]

    How J, Hobbs G. “Interferons as the First Choice of Cytoreduction in Essential Thrombocythemia and Polycythemia Vera.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 36075385 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  118. [118]

    How J, Hobbs GS. “A Practical Guide for Using Myelofibrosis Prognostic Models in the Clinic.” Journal of the National Comprehensive Cancer Network : JNCCN (2020). PMID: 32886896 ↗

    L5REVIEW_NARRATIVECited in: Management Overview, Prognosis and Prognostic Factors
  119. [119]

    McFarland DC, Polizzi H, Mascarenhas J et al.. “Psychological Symptoms Among Patients With BCR-ABL-Negative Myeloproliferative Neoplasms.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 27956541 ↗

    L4OTHERCited in: Management Overview, Special Populations
  120. [120]

    Bose P, Verstovsek S. “Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 27956543 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  121. [121]

    Mesa RA. “NCCN Debuts New Guidelines for Myeloproliferative Neoplasms.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 28515254 ↗

    L5OTHERCited in: Management Overview
  122. [122]

    Elgadi A, Wagealla M, Noorallah T et al.. “Hematologic and molecular response to ropeginterferon alfa-2b in patients with polycythemia vera: a systematic review and meta-analysis.” Annals of hematology (2026). PMID: 42068356 ↗

    L1SR_OBSCited in: Management Overview, Prognosis and Prognostic Factors
  123. [123]

    Nada EA, Elfagieh MA, Abdelsalam F et al.. “Efficacy and safety of ropeginterferon alfa-2b in the treatment of polycythemia vera: a systematic review with single arm meta-analysis.” Annals of hematology (2025). PMID: 41238945 ↗

    L1SR_OBSCited in: Management Overview, Prognosis and Prognostic Factors
  124. [124]

    Stein BL, Oh ST, Berenzon D et al.. “Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 26324368 ↗

    L5REVIEW_NARRATIVECited in: Management Overview, Prognosis and Prognostic Factors
  125. [125]

    Fleischman A, Li J, Tabban A et al.. “Telehealth-Delivered Dietary Counseling in Myeloproliferative Neoplasms: A Randomized Feasibility Study.” Nutrients (2026). PMID: 41978208 ↗

    L1RCTCited in: Management Overview, Special Populations
  126. [126]

    Yumin Z, Yuliang Z, Guozi W et al.. “Network pharmacology-based analysis of the antithrombotic clinical efficacy and antithrombotic mechanism of Huoxue Jiedu prescription in the treatment of polycythemia vera with heat toxin and blood stasis syndrome.” Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan (2025). PMID: 41376227 ↗

    L1RCTCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  127. [127]

    El Bouchtaoui M, Do Cruzeiro M, Leboeuf C et al.. “A Constitutional Activating MET Mutation Makes the Genetic Link between Malignancies and Chronic Inflammatory Diseases.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 31004003 ↗

    L4CASE_REPORTCited in: Management Overview
  128. [128]

    Inano T, Sugimoto Y, Ohishi K et al.. “Efficacy and safety of a three-step dose escalation regimen of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: a phase 3b, single-arm, multicenter study.” International journal of hematology (2026). PMID: 41801560 ↗

    L2TRIAL_NONRANDOMCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
  129. [129]

    Wernig G, Kharas MG, Okabe R et al.. “Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.” Cancer cell (2008). PMID: 18394554 ↗

    L5OTHERCited in: Management Overview, Prognosis and Prognostic Factors
  130. [130]

    Walden P, Hummel N, Kopiec A et al.. “Evaluating the feasibility of a network meta-analysis comparing treatment options in polycythemia vera.” Journal of comparative effectiveness research (2025). PMID: 41328632 ↗

    L5SR_OBSCited in: Management Overview
  131. [131]

    Lee HJ, Daver N, Kantarjian HM et al.. “The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia.” Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 23209034 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  132. [132]

    Gurska LM, Okabe R, Schurer A et al.. “Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36537918 ↗

    L5OTHERCited in: Management Overview
  133. [133]

    Patel AB, Vellore NA, Deininger MW. “New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 26933174 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  134. [134]

    Mascarenhas J, Hoffman R. “Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis.” Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 22474318 ↗

    L5OTHERCited in: Management Overview
  135. [135]

    Liu PC, Caulder E, Li J et al.. “Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.” Clinical cancer research : an official journal of the American Association for Cancer Research (2009). PMID: 19887489 ↗

    L5OTHERCited in: Management Overview
  136. [136]

    Mayo R, Bishop MW, Crawford B. “Polycythemia vera as a cause of systemic hypertension.” Pediatric nephrology (Berlin, Germany) (2026). PMID: 41670655 ↗

    L4CASE_REPORTCited in: Management Overview
  137. [137]

    Bartalucci N, Tarantino D, Loscocco GG et al.. “A Novel, Ruxolitinib-Sensitive, CCDC6::JAK2 Fusion Gene in a Patient With Atypical, JAK2 Unmutated, Polycythemia Vera-Like, Myeloproliferative Neoplasm.” American journal of hematology (2025). PMID: 41335026 ↗

    L4CASE_REPORTCited in: Management Overview
  138. [138]

    Liu W, Ren Y, Liang Y et al.. “Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study.” Hematology (Amsterdam, Netherlands) (2026). PMID: 42237068 ↗

    L3COHORTCited in: Management Overview
  139. [139]

    Chang YS, Liu CY, Chen YW et al.. “Real-World Evidence on Outcomes and Safety of Ropeginterferon Alfa-2b in Patients With Myeloproliferative Neoplasms: A Retrospective Cohort Study.” Clinical lymphoma, myeloma & leukemia (2025). PMID: 40683770 ↗

    L2COHORTCited in: Management Overview
  140. [140]

    Wu C, Wang Y, Zhang Q et al.. “BCL-XL drives fibrotic and leukemic progression in myeloproliferative neoplasms.” Frontiers in immunology (2026). PMID: 42311686 ↗

    L5OTHERCited in: Management Overview
  141. [141]

    Silver RT, Hasselbalch HC. “A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alpha.” Leukemia (2026). PMID: 41951941 ↗

    L5REVIEW_NARRATIVECited in: Management Overview
  142. [142]

    Roca Mora MM, Afzal F, Guimaraes CR et al.. “Efficacy and safety of ruxolitinib vs best available therapy for polycythemia vera: An updated systematic review and meta-analysis.” APMIS : acta pathologica, microbiologica, et immunologica Scandinavica (2024). PMID: 39377511 ↗

    L1SR_OBSCited in: Prognosis and Prognostic Factors
  143. [143]

    Mascarenhas J, Mascarenhas J, Bose P et al.. “ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia Vera.” Acta haematologica (2025). PMID: 40043697 ↗

    L1RCTCited in: Prognosis and Prognostic Factors
  144. [144]

    Heidel FH, De Stefano V, Zaiss M et al.. “Prediction of resistance to hydroxyurea therapy in patients with polycythemia vera: a machine learning study (PV-AIM) validated in a prospective interventional phase IV trial (HU-F-AIM).” Leukemia (2025). PMID: 40281326 ↗

    L1TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors, Special Populations
  145. [145]

    Yoon SY, Yoon SS, Yang DH et al.. “Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study.” International journal of cancer (2025). PMID: 40087986 ↗

    L2TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors
  146. [146]

    Sørensen AL, Skov V, Kjær L et al.. “Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera.” Blood advances (2024). PMID: 39163611 ↗

    L2TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors
  147. [147]

    Abdelfattah A, Issa GS, Al-Arareh H et al.. “Monocyte-To-Lymphocyte Ratio as a Predictor of Thrombosis Progression in Patients With Polycythemia Vera: A Retrospective Study.” International journal of laboratory hematology (2025). PMID: 41213725 ↗

    L3COHORTCited in: Prognosis and Prognostic Factors, Special Populations
  148. [148]

    Yacoub A, Abu-Zeinah G, Qin A et al.. “PARADIGM-PV: a randomized, multicenter phase 4 study to assess the efficacy and safety of ropeginterferon alfa-2b in patients with low- or high-risk polycythemia vera.” Annals of hematology (2025). PMID: 39804351 ↗

    L5TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors
  149. [149]

    Kirito K, Sugimoto Y, Gotoh A et al.. “Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera.” International journal of hematology (2024). PMID: 39361233 ↗

    L2TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors
  150. [150]

    Tønne Nesse AS, Gjelberg HK, Sandnes M et al.. “Non-MPL-W515K/L mutations in myeloproliferative neoplasms: Insights from two case reports and a review of the literature.” Expert review of hematology (2025). PMID: 40579775 ↗

    L4SR_OBSCited in: Special Populations
  151. [151]

    Emanuel RM, Dueck AC, Geyer HL et al.. “Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 23071245 ↗

    L2OTHERCited in: Special Populations
  152. [152]

    Geron I, Abrahamsson AE, Barroga CF et al.. “Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors.” Cancer cell (2008). PMID: 18394555 ↗

    L2OTHERCited in: Special Populations
  153. [153]

    Kalota A, Jeschke GR, Carroll M et al.. “Intrinsic resistance to JAK2 inhibition in myelofibrosis.” Clinical cancer research : an official journal of the American Association for Cancer Research (2013). PMID: 23386690 ↗

    L4OTHERCited in: Special Populations
  154. [154]

    De Fazio L, Molica M, Simio C et al.. “Managing myelofibrosis in the frailty era: the expanding role of JAK inhibitors.” Leukemia & lymphoma (2026). PMID: 41982071 ↗

    L5REVIEW_NARRATIVECited in: Special Populations

Revision History

All updates applied to this page

Loading revisions…